Movatterモバイル変換


[0]ホーム

URL:


SG11201810355SA - Anti-axl tyrosine kinase receptor antibodies and uses thereof - Google Patents

Anti-axl tyrosine kinase receptor antibodies and uses thereof

Info

Publication number
SG11201810355SA
SG11201810355SASG11201810355SASG11201810355SASG11201810355SASG 11201810355S ASG11201810355S ASG 11201810355SASG 11201810355S ASG11201810355S ASG 11201810355SASG 11201810355S ASG11201810355S ASG 11201810355SASG 11201810355S ASG11201810355S ASG 11201810355SA
Authority
SG
Singapore
Prior art keywords
antigen
binding
international
singapore
tyrosine kinase
Prior art date
Application number
SG11201810355SA
Inventor
Mei Yee Vanessa Ding
Boon Hwa Andre Choo
Wey Jia Fong
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & ResfiledCriticalAgency Science Tech & Res
Publication of SG11201810355SApublicationCriticalpatent/SG11201810355SA/en

Links

Classifications

Landscapes

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101/110 111010101111101011111 0 0111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2017/200493 Al 23 November 2017 (23.11.2017) WIPO I PCT (51) International Patent Classification: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, C07K 16/30 (2006.01) A61P 35/00 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, A61K 39/395 (2006.01) G01N 33/53 (2006.01) KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/SG2017/050266 Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) (22) International Filing Date: 22 May 2017 (22.05.2017) Published: — with international search report (Art. 21(3)) (25) Filing Language: English — with sequence listing part of description (Rule 5.2(a)) (26) Publication Language: English (30) Priority Data: 10201604090Y 20 May 2016 (20.05.2016) SG (71) Applicant: AGENCY FOR SCIENCE, TECHNOLO- GY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis North Tower, Singapore 138632 (SG). (72) Inventors: DING, Mei Yee Vanessa; c/o Bioprocessing Technology Institute, 20 Biopolis Way, #06-01, Singapore 138668 (SG). CHOO, Boon Hwa Andre; c/o Bioprocess- ing Technology Institute, 20 Biopolis Way, #06-01, Sin- gapore 138668 (SG). FONG, Wey Jia; c/o Bioprocessing = Technology Institute, 20 Biopolis Way, #06-01, Singapore = 138668 (SG). Agent: SPRUSON & FERGUSON (ASIA) PTE LTD; = (74) — P.O. Box 1531, Robinson Road Post Office, Singapore 903031 (SG). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, = (81) = = DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, = = KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, = MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, = PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = = = Designated States (unless otherwise indicated, for every (84) = kind of regional protection available): ARIPO (BW, GH, — GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, — 1-1 en (54) Title: ANTI-AXL TYROSINE KINASE RECEPTOR ANTIBODIES AND USES THEREOF 0\ i v (57) : The present invention relates to antigen-binding proteins, or antigen-binding fragments thereof that bind to a glycan © on the AXL receptor tyrosine kinase. The present invention also relates to antigen-binding proteins, or antigen-binding fragment con- con- © jugated to a radioisotope or cytotoxin, and wherein said antigen-binding proteins, or antigen-binding fragment is internalised into a © ---. cell upon binding to AXL receptor tyrosine kinase. Compositions comprising a physiologically acceptable carrier and a therapeutically I N effective amount of the antigen-binding protein, or antigen- binding fragment thereof, therapeutic use of the antigen-binding protein, 1-1 © or ei antigen-binding fragment thereof, methods for detecting cancer as well as kits when used in such methods are also provided. O
SG11201810355SA2016-05-202017-05-22Anti-axl tyrosine kinase receptor antibodies and uses thereofSG11201810355SA (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
SG10201604090Y2016-05-20
PCT/SG2017/050266WO2017200493A1 (en)2016-05-202017-05-22Anti-axl tyrosine kinase receptor antibodies and uses thereof

Publications (1)

Publication NumberPublication Date
SG11201810355SAtrue SG11201810355SA (en)2018-12-28

Family

ID=60326074

Family Applications (1)

Application NumberTitlePriority DateFiling Date
SG11201810355SASG11201810355SA (en)2016-05-202017-05-22Anti-axl tyrosine kinase receptor antibodies and uses thereof

Country Status (5)

CountryLink
US (1)US11306153B2 (en)
EP (1)EP3458482A4 (en)
CN (1)CN109476757B (en)
SG (1)SG11201810355SA (en)
WO (1)WO2017200493A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN113045664B (en)*2019-11-282023-05-12尚健单抗(北京)生物技术有限公司Isolated antigen AXL-binding protein and use thereof
CN115125272B (en)*2021-03-292024-04-19复旦大学 A CAR-T therapeutic vector and its construction method and application

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EP2582729A4 (en)*2010-06-182014-05-28Hoffmann La Roche ANTI-AXL ANTIBODIES, AND METHODS OF USE.
EP2589609A1 (en)2011-11-032013-05-08Pierre Fabre MedicamentAntigen binding protein and its use as addressing product for the treatment of cancer
WO2014174111A1 (en)2013-04-262014-10-30Pierre Fabre MedicamentAxl antibody-drug conjugate and its use for the treatment of cancer
WO2015095766A2 (en)*2013-12-202015-06-25Stem Centrx, Inc.Novel anti-lingo1 antibodies and methods of use
ME03665B (en)2014-07-112020-10-20Genmab AsAntibodies binding axl
JP6913030B2 (en)2015-05-182021-08-04アジェンシス,インコーポレイテッド Antibodies that bind to the AXL protein
WO2017189959A1 (en)2016-04-292017-11-02Voyager Therapeutics, Inc.Compositions for the treatment of disease

Also Published As

Publication numberPublication date
EP3458482A1 (en)2019-03-27
WO2017200493A1 (en)2017-11-23
CN109476757A (en)2019-03-15
US11306153B2 (en)2022-04-19
CN109476757B (en)2022-06-07
US20200317812A1 (en)2020-10-08
EP3458482A4 (en)2020-01-15

Similar Documents

PublicationPublication DateTitle
SG11201809344QA (en)Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201809374VA (en)Cd40l-fc fusion polypeptides and methods of use thereof
SG11201901126UA (en)Combination therapy for cancer
SG11201903830TA (en)Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11201903857UA (en)Antibodies to pd-1 and uses thereof
SG11201808622SA (en)Chimeric receptors to flt3 and methods of use thereof
SG11201909963YA (en)Methods for treating dravet syndrome
SG11201803703UA (en)Anti-complement factor c1q fab fragments and uses thereof
SG11201907753TA (en)Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201810933QA (en)Anti-c5 antibodies and uses thereof
SG11201810697QA (en)Chimeric antigen receptor and car-t cells that bind bcma
SG11201407580YA (en)Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201809857TA (en)Anti-CTLA-4 Antibodies
SG11201806515RA (en)Eribulin-based antibody-drug conjugates and methods of use
SG11201810420YA (en)Antibodies to alpha-synuclein and uses thereof
SG11201900772YA (en)Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201807593TA (en)Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201907889YA (en)Glycan-interacting compounds and methods of use
SG11201903771XA (en)Binding molecules specific for asct2 and uses thereof
SG11201908238SA (en)Anti-c5 antibodies and uses thereof
SG11201809252YA (en)Methods for determining dpp3 and therapeutic methods
SG11201810280YA (en)Spiro-lactam nmda receptor modulators and uses thereof
SG11201806121PA (en)Ror2 antibody compositions and related methods
SG11201901597UA (en)Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
SG11201809764XA (en)Humanized anti-il-1r3 antibodies

[8]ページ先頭

©2009-2025 Movatter.jp